17
Background:
In low- and middle-income countries, patients face high out-of-pocket expenses for consultations, diagnostics, chemotherapy, radiotherapy, and surgery contributing to treatment delays or discontinuation. COST-FIN is the first randomized controlled trial evaluating whether structured financial nav...
D. Ebekue, F. Wuraola, Titilope Ogunniyi et al.· JCO Oncology Practice· 0 citations
Within COST- FIN, RAs, data quality oversight, and in-country project management were essential to trial operations, financial data integrity, and cross-site implementation fidelity.
Z. Adegbite, Clement Awe, T. Aduloju et al.· JCO Global Oncology· 0 citations
Findings suggest certain risk factors are shared across populations, representing a critical first step in defining CRC risk profiles to tailor prevention and early detection efforts in the region.
O. Alatise, Noah C. Peeri, F. Abdulkareem et al.· JAMA Network Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
